Enzogenol (Pine Bark Extract)

Enzogenol is a standardized pine bark extract containing proanthocyanidins that inhibits NF-κB signaling pathways. It demonstrates anti-inflammatory effects by reducing TNF-α-induced endothelial cell adhesion and provides antioxidant protection through reactive oxygen species suppression.

Origin & History

Enzogenol is a branded dietary supplement derived from the bark of Pinus radiata (radiata pine) trees grown in New Zealand. It is produced through a pure water-only extraction process that yields a dry powder rich in natural phenolic compounds, primarily proanthocyanidins (>80% by weight), taxifolin (1-2%), other flavonoids, phenolic acids (up to 8%), and carbohydrates (5-10%).

Historical & Cultural Context

No historical or traditional medicine use is documented for Enzogenol or Pinus radiata bark in the research. Enzogenol is a modern branded extract developed in New Zealand using contemporary water extraction methods, with no reported links to traditional medicine systems.

Health Benefits

• Anti-inflammatory effects: In vitro studies showed Enzogenol (5-50 μg/mL) reduced TNF-α-induced adhesion molecules and monocyte adhesion in human endothelial cells via NF-κB inhibition (preliminary evidence)
• Antioxidant activity: Demonstrates superior reactive oxygen species suppression compared to vitamin C, primarily through proanthocyanidins (in vitro evidence)
• Cardiovascular support: May help reduce atherosclerosis-related inflammation by inhibiting monocyte transmigration and MMP-9 activity (preliminary evidence from cell studies)
• General safety profile: Toxicology studies in rats, dogs, and humans showed no significant adverse effects (safety data available)
• Brain function support: Referenced by manufacturers but no specific clinical trials provided in research dossier (insufficient evidence)

How It Works

Enzogenol's proanthocyanidins inhibit the NF-κB transcription factor pathway, reducing expression of inflammatory adhesion molecules like VCAM-1 and ICAM-1 in endothelial cells. The extract suppresses TNF-α-induced monocyte adhesion by blocking nuclear translocation of NF-κB subunits. Its antioxidant activity stems from direct reactive oxygen species scavenging and upregulation of endogenous antioxidant enzyme systems.

Scientific Research

The research dossier provides limited clinical trial data specific to Enzogenol, with most evidence coming from in vitro studies on human umbilical vein endothelial cells showing anti-inflammatory effects. Safety has been assessed through toxicology studies in rats, dogs, and humans, though specific RCTs for efficacy and PMIDs are not provided in the available research.

Clinical Summary

Current evidence for Enzogenol comes primarily from in vitro studies using human endothelial cell cultures. Research demonstrates that concentrations of 5-50 μg/mL effectively reduce inflammatory markers and cellular adhesion. The extract shows superior antioxidant capacity compared to other pine bark extracts in laboratory testing. However, human clinical trials with measured health outcomes are lacking, limiting conclusions about therapeutic efficacy.

Nutritional Profile

Enzogenol is a standardized pine bark extract (derived from Pinus radiata) composed predominantly of bioactive polyphenols with negligible macronutrient content at typical supplemental doses (150-480 mg/day). Key bioactive compounds include: proanthocyanidins (oligomeric and polymeric forms, estimated 80-90% of dry weight), catechin and epicatechin monomers, taxifolin (dihydroquercetin), ferulic acid, and caffeic acid. Proanthocyanidins are primarily B-type dimers and trimers, which confer the primary antioxidant and anti-inflammatory activity. Minimal caloric contribution (<2 kcal per typical dose). No meaningful protein, fat, or dietary fiber content at supplemental doses. No significant vitamin or mineral content intrinsic to the extract itself. Bioavailability: Low-molecular-weight monomers (catechin, epicatechin) are relatively well-absorbed in the small intestine; larger oligomeric proanthocyanidins undergo partial colonic fermentation into smaller phenolic metabolites (e.g., valerolactones, phenylpropionic acids) before systemic absorption, resulting in variable and generally moderate bioavailability. Peak plasma concentrations of catechin monomers typically reached within 1-2 hours post-ingestion. Water-soluble formulation of Enzogenol enhances dispersibility compared to some other pine bark extracts.

Preparation & Dosage

Clinically studied dosages in humans are not specified in the available research. In vitro studies used concentrations of 5-50 μg/mL (non-toxic up to 25 μg/mL). The extract is standardized to >80% proanthocyanidins in powder form. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Vitamin E, Coenzyme Q10, Resveratrol, Green Tea Extract

Safety & Interactions

Enzogenol appears well-tolerated based on its similarity to other pine bark extracts, though specific safety data is limited. Potential interactions may occur with anticoagulant medications due to possible effects on platelet function. Individuals with pine allergies should exercise caution when considering supplementation. Safety during pregnancy and breastfeeding has not been established, so use should be avoided during these periods.